Pulmonary hypertension

This phase 2 trial tested an experimental biologic called KER-012 in 113 adults with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. Participants received either KER-012 or a placebo as a shot every 4 weeks, on top of their usual PAH…

This study looked at whether the drug riociguat could improve right heart size and function in people with two types of pulmonary hypertension (PAH and CTEPH). It planned to enroll 30 adults, but was terminated early, so results are limited. The goal was to use echocardiograms to…

This Phase 3 trial tested the drug sotatercept in 321 people newly diagnosed with intermediate- or high-risk pulmonary arterial hypertension (PAH). Participants received either sotatercept or a placebo added to their usual PAH therapy. The goal was to see if sotatercept could del…

This study looked at the long-term safety of an inhaled drug called treprostinil in people who have both pulmonary hypertension (high blood pressure in the lungs) and COPD. It included 41 adults who had already completed a previous study. The trial was terminated early, and the m…

This study tested a drug called CardiolRx in 90 hospitalized COVID-19 patients who also had heart disease or risk factors like diabetes or high blood pressure. The goal was to see if the drug could lower the chance of death, needing intensive care, or having heart problems. The t…

This study looked at the long-term safety of the drug LTP001 in people with pulmonary arterial hypertension (PAH), a serious lung condition. It was an open-label extension for patients who had completed a previous study. However, the study was terminated early, and no one reached…

This study tested the drug riociguat in people with early pulmonary vascular disease, a condition where blood vessels in the lungs narrow, making the heart work harder. The trial included 35 adults with connective tissue disease or an inherited form. Participants received either …

This study tested an experimental drug called LTP001 in 47 people with pulmonary arterial hypertension (PAH), a condition where high blood pressure damages the arteries in the lungs. The goal was to see if LTP001 could improve blood flow and exercise ability. However, the trial w…

This was a very early (Phase 1) study testing a drug called HS135 in obese patients who have both pulmonary hypertension and a type of heart failure called HFpEF. The trial was terminated after enrolling only 4 people, so we have no useful information on whether HS135 is safe or …

This study explored whether a special type of MRI using inhaled xenon gas could detect changes in the small blood vessels of the lungs in people with pulmonary hypertension. The goal was to see if this imaging method could track disease progression or response to treatment. Howev…

This study looked at how two common pain relievers—celecoxib (a Coxib) and naproxen (an NSAID)—affect blood clotting in people with rheumatoid arthritis who also have heart disease or are at high risk for it. All participants took low-dose aspirin daily. The goal was to see if on…